IOncology

Breast cancer remains one of the most significant threats to women’s health. The continuous evolution of treatment strategies reflects the rapid advancement of medical technology. In recent years, precision treatment for breast cancer has become a focal point of research, with accurate target selection and innovative drug development being of paramount importance. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Chunfang Hao from Tianjin Cancer Hospital Airport Hospital delivered a presentation titled "The Significance of Targets in Breast Cancer Diagnosis and Treatment," offering her unique insights on precision treatment. Following the session, Oncology Frontier interviewed Professor Hao, who provided an in-depth discussion on the critical role of target selection, progress in emerging drugs and therapies, and the future directions in breast cancer diagnosis and treatment.

Breast cancer remains a major threat to women’s health, with continuous advancements in treatment strategies being a focal point for the medical community. In China, as the concept of precision medicine gains momentum, systematic breast cancer treatment is gradually moving towards more personalized and precise approaches. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) during the Breast Oncology Integrative Rehabilitation session, Dr. Man Li from The Second Hospital of Dalian Medical University delivered a presentation titled “Current Status and Advances in Systematic Breast Cancer Treatment in China”, offering an overview of treatment strategies for different subtypes of breast cancer. In an interview with Oncology Frontier, Professor Li discussed the challenges facing systematic treatment and the future directions of breast cancer therapy, emphasizing the transformative role of precision medicine in shaping treatment paradigms.

Breast cancer remains a major threat to women’s health, and early screening plays a crucial role in reducing both incidence and mortality. However, compared to developed countries in Europe and North America, China still faces numerous challenges in breast cancer screening. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) during the Breast Oncology Integrative Rehabilitation session, Dr. Nanlin Li from Xijing Hospital of the Air Force Medical University delivered a report titled “Strategies and Gaps in Breast Cancer Screening for Chinese Women”, providing an in-depth analysis of the current state of breast cancer screening in China and the challenges faced. In an interview with Oncology Frontier, Professor Li highlighted that while progress has been made in recent years, obstacles such as the large population size, insufficient funding, a shortage of trained personnel, and low public awareness continue to limit the full implementation of screening efforts. He called on more women to recognize the importance of screening and encouraged collective efforts from governments and society to improve coverage and safeguard women's health.

At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) held from November 14–17 in Xi’an, Dr. Yinying Wu from The First Affiliated Hospital Xi'an Jiao Tong University delivered a comprehensive lecture titled “Advances in CLDN18.2-Positive Gastric Cancer Research.” The presentation delved into the role of CLDN18.2 protein in gastric cancer, advancements in drug therapies, and preliminary explorations into drug and immunotherapy combinations.

Editor's Note:Enhanced Recovery After Surgery (ERAS) represents a cornerstone concept in modern perioperative management. It employs a series of evidence-based interventions designed to mitigate or alleviate the body's stress responses,…

Neoadjuvant therapy for locally advanced colorectal cancer has made significant progress over the past 20 years, but it still faces limitations such as adverse reactions, organ dysfunction, and unsatisfactory control of distant metastasis. In recent years, with the improvement of surgical techniques and further development of tumor molecular typing research, how to further improve local control rates, reduce distant metastasis rates, and even spare surgery and preserve organs based on clinical response has become the current patient needs and research objectives.

At the 2024 Breast Cancer Standardized Diagnosis and Treatment & Quality Control Conference (November 8–10, Beijing), Dr. Ying Fan from the Cancer Hospital Chinese Academy of Medical Sciences, presented the key updates to the 2024 Chinese Advanced Breast Cancer Clinical Guidelines (ABCC). The updated ABCC guidelines include treatment recommendations for different breast cancer subtypes and introduce a new chapter on managing adverse events. Below is a summary of the key updates to the guidelines.

The 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO) and the 4th Asian Oncology Summit (AOS), hosted by the Chinese Anti-Cancer Association (CACA) in collaboration with the Chinese Academy of Integrative Medicine and the Shaanxi Anti-Cancer Association, took place from November 14–17 in the ancient city of Xi'an. This prestigious event featured specialized summits co-organized by CACA and global cancer organizations, including the National Comprehensive Cancer Network (NCCN), Union for International Cancer Control (UICC), Society of Latin American and Caribbean Oncology (SLACOM), and International Society of Breast Disease (SIS), to foster international collaboration in cancer prevention and treatment.

The 27th National Conference of Clinical Oncology and 2024 CSCO Academic Annual Meeting, jointly organized by the Chinese Society of Clinical Oncology and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Xiamen from September 25 to 29, 2024. The conference included multiple sessions on lung cancer, which brought together the latest advances and frontiers in lung cancer research from both domestic and international perspectives. During the conference, Oncology Frontier invited Dr. Wenhua Liang from The First Affiliated Hospital of Guangzhou Medical University to share new clinical developments in immunotherapy combinations for non-small cell lung cancer (NSCLC) and recent breakthroughs in precision diagnostic pathways.